Vitreous inflammatory factors and macular oedema

British Journal of Ophthalmology

Volumn 96, Issue 2, 2012, Pages 302-304

  Funatsu, Hideharu ^a   Noma, Hidetaka ^a   Mimura, Tatsuya ^b   Eguchi, Shuichiro ^c  

^a Tokyo Women s Medical University   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Eguchi Eye Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINA MACULA EDEMA; VITREOUS BODY;

AGED; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84856046168     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.181222     Document Type: Article

References (17)

1. Jousssen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-2. (Pubitemid 39561611)
2. Zhang SX, Wang JJ, Gao G, et al. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006;20:323-5. (Pubitemid 46671158)
3. Lam DSC, Chan CKM, Mohamed S, et al. A prospective randomized trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007;91:199-203. (Pubitemid 46202869)
4. Ip MS, Scott IU, Van Veldhuisen PC, et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion. The standard care vs. corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-14.
5. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-7.
6. Spaide RF, Chang LS, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
7. Paccla L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone acetonide versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008;92:76-80.
8. Cheng KS, Wu WC, Chen KJ. Intravitreal triamcinolone acetonide vs. bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye 2009;23:2023-33.
9. Wuo WC, Cheng KC, Jiang Wu HJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye 2009;23:2215-22.
10. Kim NR, Kim YJ, Chin HS, et al. Optical coherence tomographic patterns in diabetic macular oedema. Predictions of visual outcome after focal laser photocoagulation. Br J Ophthalmol 2009;93:901-5.
11. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003;110:1690-6. (Pubitemid 37025424)
12. Noma H, Funatsu H, Mimura T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 2009;116:87-93.
13. Campochiaro PA, Choy DF, Do DV, et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 2009;116:2158-64.
14. Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefe's Arch Clin Exp Ophthalmol 2005;243:3-8.
15. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humor levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008;22:42-8.
16. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse macular edema. Am J Ophthalmol 2008;145:854-61.
17. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blooderetinal and bloodeaqueous barrier breakdown. Exp Eye Res 2005;80:249-58.